XML 14 R14.htm IDEA: XBRL DOCUMENT
v3.20.1

Commitments and Contingencies | 12 Months Ended
--- | ---
Dec. 31, 2019
Commitments And Contingencies Disclosure [Abstract] |
Commitments and Contingencies |
7. | Commitments and Contingencies
Leases At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company calculates the associated lease liability and corresponding right-of-use asset upon lease commencement using a discount rate based on the rate implicit in the lease or an incremental borrowing rate commensurate with the term of the lease. The Company records lease liabilities within current liabilities or long-term liabilities based upon the length of time associated with the lease payments. The Company records its operating lease right-of-use assets as long-term assets. Right-of-use assets for financing leases are recorded within property and equipment, net in the Balance Sheet. Leases with an initial term of 12 months or less are not recorded on the Balance Sheet. Instead, the Company recognizes lease expense for these leases on a straight-line basis over the lease term. In connection with certain operating leases, the Company has security deposits recorded and maintained as restricted cash totaling $40 thousand as of December 31, 2019. The Company leases laboratory, office and storage facilities in San Antonio, Texas, under operating lease agreements that expire in 2028. The Company also leases certain office space in Austin, Texas under a month-to-month operating lease agreement. In addition, the Company leases certain equipment under various operating and finance leases. The lease agreements generally provide for periodic rent increases, and renewal and termination options. The Company’s lease agreements do not contain any material variable lease payments, residual value guarantees or material restrictive covenants. Certain leases require the Company to pay taxes, insurance, and maintenance. Payments for the transfer of goods or services such as common area maintenance and utilities represent non-lease components. The Company elected the package of practical expedients and therefore does not separate non-lease components from lease components. The table below summarizes the Company’s lease liabilities and corresponding right-of-use assets (in thousands, except years and rates):
|  | December 31, 2019 |
Assets |  |  |  |
Operating |  | $ | 781 |
Financing |  |  | 134 |
Total leased assets |  | $ | 915 |
Liabilities |  |  |  |
Current: |  |  |  |
Operating |  | $ | 147 |
Financing |  |  | 120 |
Noncurrent: |  |  |  |
Operating |  | $ | 646 |
Financing |  |  | 8 |
Total lease liabilities |  | $ | 921 |
Weighted-average remaining lease term (years) - operating leases |  |  | 6.89 |
Weighted-average remaining lease term (years) - finance leases |  |  | 1.08 |
Weighted-average discount rate - operating leases |  |  | 7.93 | %
Weighted-average discount rate - finance leases |  |  | 5.00 | %
The table below summarizes the Company’s lease costs from its consolidated statements of operations, and cash payments from its consolidated statements of cash flows during year ended December 31, 2019.
|  | Year ended December 31, 2019 |
Lease expense: |  |  |  |
Operating lease expense |  | $ | 225 |
Finance lease expense: |  |  |  |
Depreciation of right-of-use assets |  |  | 116 |
Interest expense on lease liabilities |  |  | 9 |
Total lease expense |  | $ | 350 |
Cash payment information: |  |  |  |
Operating cash used for operating leases |  | $ | 213 |
Financing cash used for financing leases |  |  | 131 |
Total cash paid for amounts included in the measurement of lease liabilities |  | $ | 344 |
Total rent expenses for the year ended December 31, 2019 was $0.7 million, which includes leases in the table above, month-to-month operating leases, and common area maintenance charges. The Company’s future minimum annual lease payments under operating and financing leases at December 31, 2019 are as follows (in thousands):
|  | Financing Leases |  |  | Operating Leases |
2020 |  |  | 123 |  |  |  | 211 |
2021 |  |  | 7 |  |  |  | 183 |
2022 |  |  | — |  |  |  | 123 |
2023 |  |  | — |  |  |  | 100 |
Thereafter |  |  | — |  |  |  | 447 |
Total minimum lease payments |  | $ | 130 |  |  | $ | 1,064 |
Less: amount representing interest |  |  | (2 | ) |  |  | (271 | )
Present value of obligations under leases |  |  | 128 |  |  |  | 793 |
Less: current portion |  |  | (120 | ) |  |  | (147 | )
Noncurrent lease obligations |  | $ | 8 |  |  | $ | 646 |
Prior to December 2019, the Company also maintained office space for its former corporate headquarters in San Diego, California (the “Lease”). The initial term of the Lease is 63 months and may be extended upon mutual agreement. In connection with a restructuring announced in September 2017, the Company began negotiations with the landlord and in February 2018, announced a buy-out of its obligations with the Lease of approximately $0.6 million, included in the general and administrative expenses. As of December 31, 2018, future minimum lease payments under the Company’s lease obligations under ASC 840 were as follows:
Years Ending December 31, |  | Obligation |
2019 |  | $ | 1,282 |
2020 |  |  | 638 |
2021 |  |  | 638 |
2022 |  |  | 192 |
Total |  | $ | 2,750 |
Rent expenses, which includes common area maintenance, for the year ended December 31, 2018 was $1.9 million. Other commitments We have entered into agreements with various research organizations for pre-clinical and clinical development studies, which have provisions for cancellation. Under the terms of these agreements, the vendors provide a variety of services including conducting research, recruiting and enrolling patients, monitoring studies and data analysis. Payments under these agreements typically include fees for services and reimbursement of expenses. The timing of payments due under these agreements is estimated based on current study progress. As of December 31, 2019, we have clinical research study obligations of $0.9 million, which is expected to be paid within a year. We are subject to various claims and contingencies related to legal proceedings. Due to their nature, such legal proceedings involve inherent uncertainties including, but not limited to, court rulings, negotiations between affected parties and governmental actions. Management assesses the probability of loss for such contingencies and accrues a liability and/or discloses the relevant circumstances, as appropriate. On July 25, 2019, Tap Advisors LLC (“Tap”) filed suit against the Company in the Supreme Court of the State of New York, County of New York, alleging the Company breached an agreement made in 2017, whereby Tap would provide certain financial advisory services to the Company. Tap sought to recover fees of approximately $3.7 million (plus attorneys’ fees) that allegedly had not been paid by the Company related to the sale of its Cell Therapy business in April 2019. In December 2019, the Company settled the Tap litigation with cash payment of $0.7 million, which is included in the loss from discontinued operations for the year ended December 31, 2019.

X
- References No definition available. + Details
Name: | us-gaap_CommitmentsAndContingenciesDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for commitments and contingencies. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -URI http://asc.fasb.org/topic&trid=2127136 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 440 -URI http://asc.fasb.org/topic&trid=2144648 + Details
Name: | us-gaap_CommitmentsAndContingenciesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration